rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Lifecore Biomedical, Inc.

LFCR · Nasdaq

Health CareBiotechnologyAbove a falling average

LFCR stood above a rising 150-day average in 14 of the last 52 weekly readings, and has been out of that trend for the last 37 weeks. It is 30.1% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 37
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
96 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$9.5M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders96-2 on the quarter
New · exited18 · 20
Reported value$133.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
WYNNEFIELD CAPITAL INCunchanged · filed 14 Aug 20264,703,216$24.7M00.0%
Legion Partners Asset Management, LLCunchanged · filed 14 Aug 20264,461,823$23.4M00.0%
Greenhaven Road Investment Management, L.P.reduced · filed 14 Aug 20263,190,769$16.8M-346,804−9.8%
325 CAPITAL LLCadded · filed 14 Aug 20262,895,881$15.2M+733,415+33.9%
BlackRock, Inc.added · filed 7 Aug 20262,013,093$10.6M+135,788+7.2%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,288,621$6.8M-1,515−0.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026855,500$4.5M+40,393+5.0%
MORGAN STANLEYadded · filed 13 Aug 2026769,360$4.0M+4,626+0.6%
STATE STREET CORPadded · filed 7 Aug 2026668,031$3.5M+26,025+4.1%
Quinn Opportunity Partners LLCunchanged · filed 14 Aug 2026453,495$2.4M00.0%
31 Mar 2023 – 30 Jun 2026
648197Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Christopher S. Kiper Company insiderDirector, 10% owner · last 4 Jun 20260 · 0
Humberto Calheiros Antunes Company insiderDirector · last 4 Jun 20260 · 0
Jason Aryeh Company insiderDirector · last 4 Jun 20260 · 0
Joshua Schechter Company insiderDirector · last 4 Jun 20261 · 0
Legion Partners, L.p. I Company insiderDirector, 10% owner · last 4 Jun 20260 · 0
Lovas Katrina Houde Company insiderDirector · last 4 Jun 20260 · 0
Matthew E. Korenberg Company insiderDirector · last 4 Jun 20260 · 0
Nelson Obus Company insiderDirector · last 4 Jun 202623 · 0
Paul Harold Johnson Company insiderDirector · last 4 Jun 20260 · 0
Paul Josephs Company insiderChief Executive Officer · last 20 May 20261 · 0
Thomas D. Salus Company insiderChief Legal & Administration · last 14 Apr 20260 · 0
Ryan David Lake Company insiderChief Financial Officer · last 3 Sep 20250 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 25 May 202531.3%
Operating profit marginFY 2025 · to 25 May 2025-13.4%
Free cash flow marginFY 2025 · to 25 May 2025-10.6%
Return on capital employedFY 2025 · to 25 May 2025-8.2%
Interest coverFY 2025 · to 25 May 2025-0.79×
Research spendFY 2025 · to 25 May 20256.4%
Share count trendFY 2025 · to 31 Jul 20251.0%
Cash and equivalentsFY 2025 · to 25 May 2025$8.3M
Free cash flowFY 2025 · to 25 May 2025−$13.6M

Analyst forecasts

No analyst forecasts yet.